Recently, the stimulator of interferon genes (STING) pathway was found to be critical to tumor immunotherapy (4–6); STING is an endoplasmic reticulum (ER) protein that is expressed in both cancer cells and immune cells (7), which can be activated by STING agonists (8, 9). This evidence concerns the gene STING1 and cancer.